Wordt geladen...
Dabrafenib and trametinib in BRAFV600E mutated glioma
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with...
Bewaard in:
| Gepubliceerd in: | CNS Oncol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Future Medicine Ltd
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004887/ https://ncbi.nlm.nih.gov/pubmed/28984141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2017-0006 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|